You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

LIDOCAINE AND PRILOCAINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lidocaine And Prilocaine patents expire, and when can generic versions of Lidocaine And Prilocaine launch?

Lidocaine And Prilocaine is a drug marketed by Alembic, Encube, Fougera Pharms, Hikma, Padagis Us, Pai Holdings Pharm, and Rhodes Pharms. and is included in seven NDAs.

The generic ingredient in LIDOCAINE AND PRILOCAINE is lidocaine; prilocaine. There are twenty-nine drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the lidocaine; prilocaine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lidocaine And Prilocaine

A generic version of LIDOCAINE AND PRILOCAINE was approved as lidocaine; prilocaine by FOUGERA PHARMS on August 18th, 2003.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LIDOCAINE AND PRILOCAINE?
  • What are the global sales for LIDOCAINE AND PRILOCAINE?
  • What is Average Wholesale Price for LIDOCAINE AND PRILOCAINE?
Summary for LIDOCAINE AND PRILOCAINE
US Patents:0
Applicants:7
NDAs:7
Finished Product Suppliers / Packagers: 8
Raw Ingredient (Bulk) Api Vendors: 5
Clinical Trials: 75
Patent Applications: 100
What excipients (inactive ingredients) are in LIDOCAINE AND PRILOCAINE?LIDOCAINE AND PRILOCAINE excipients list
DailyMed Link:LIDOCAINE AND PRILOCAINE at DailyMed
Drug patent expirations by year for LIDOCAINE AND PRILOCAINE
Recent Clinical Trials for LIDOCAINE AND PRILOCAINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Indonesia Endowment Fund for EducationPhase 4
Universitas Sebelas MaretPhase 4
Cairo UniversityN/A

See all LIDOCAINE AND PRILOCAINE clinical trials

Pharmacology for LIDOCAINE AND PRILOCAINE

US Patents and Regulatory Information for LIDOCAINE AND PRILOCAINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alembic LIDOCAINE AND PRILOCAINE lidocaine; prilocaine CREAM;TOPICAL 213923-001 Apr 8, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Rhodes Pharms LIDOCAINE AND PRILOCAINE lidocaine; prilocaine CREAM;TOPICAL 213253-001 Sep 21, 2020 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hikma LIDOCAINE AND PRILOCAINE lidocaine; prilocaine CREAM;TOPICAL 076290-001 Sep 25, 2003 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Encube LIDOCAINE AND PRILOCAINE lidocaine; prilocaine CREAM;TOPICAL 076320-001 Aug 27, 2003 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fougera Pharms LIDOCAINE AND PRILOCAINE lidocaine; prilocaine CREAM;TOPICAL 076453-001 Aug 18, 2003 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Pai Holdings Pharm LIDOCAINE AND PRILOCAINE lidocaine; prilocaine CREAM;TOPICAL 205887-001 Jun 29, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for LIDOCAINE AND PRILOCAINE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Recordati Ireland Ltd. Fortacin lidocaine, prilocaine EMEA/H/C/002693
Treatment of primary premature ejaculation in adult men.
Authorised no no no 2013-11-15
Plethora Pharma Solutions Limited Senstend lidocaine, prilocaine EMEA/H/C/005298
Senstend is indicated for the treatment of primary premature ejaculation in adult men.
Withdrawn no no no 2019-11-14
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.